Could a Half-Dose of a common drug prevent a painful complication just as well?
NCT ID NCT07088757
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares a low dose (50 mg) versus the standard dose (100 mg) of indomethacin given rectally before ERCP to prevent post-procedure pancreatitis. About 1,366 adults undergoing ERCP will be randomly assigned to one of the two doses in a double-blind fashion. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
indomethacin (a nonsteroidal anti-inflammatory drug given as a rectal suppository)
What this could lead to
If successful, a lower dose could prevent post-ERCP pancreatitis just as effectively as the standard dose, while reducing side effects like bleeding or kidney problems.
What could go wrong
This is a non-inferiority trial, so the lower dose might prove slightly less effective. The study is also limited to adults in China, so results may not apply everywhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST ERCP PANCREATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiaxing University
NOT_YET_RECRUITINGZhejiang, China
Contact Phone: •••-•••-••••
-
Changhai Hospital
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Dongyang People's Hospital
NOT_YET_RECRUITINGZhejiang, China
Contact Phone: •••-•••-••••
-
First Affiliated Hospital of Ningbo University
NOT_YET_RECRUITINGZhejiang, China
Contact Phone: •••-•••-••••
-
Jinhua Central Hospital
NOT_YET_RECRUITINGZhejiang, China
Contact Phone: •••-•••-••••
-
People's Hospital of Quzhou
NOT_YET_RECRUITINGZhejiang, China
Contact Phone: •••-•••-••••
-
Ruijin Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
-
Shanghai General Hospital
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
-
Shaoxing People's Hospital
NOT_YET_RECRUITINGZhejiang, China
Contact Phone: •••-•••-••••
-
Sir Run Run Shaw Hospital
RECRUITINGZhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taizhou Enze Medical Center Group
RECRUITINGZhejiang, China
Contact Phone: •••-•••-••••
-
Zhuji People's Hospital of Zhejiang Province
NOT_YET_RECRUITINGZhejiang, China
Contact Phone: •••-•••-••••